GreenLight Biosciences Inc. will partner with a special-purpose acquisition company to open its doors to an RNA technology company in a transaction valuing about $ 1.5 billion, the two companies said.
GreenLight is the developer of mRNA vaccines to combat Covid-19 and other diseases, and is simultaneously working on RNA-based sustainable alternatives to pesticides and herbicides. The Boston-based company wants to tackle the challenge of large-scale production of vaccines and other RNA products by reproducing cell proliferation without the actual use of live cells.
GreenLight is an investment bank, Canaccord Genuity Group Inc. SPACEn vironmental Impact Acquisition Corp supported by. Is integrated with.
Founded in 2008, Green Light aims to take advantage of recent advances in technology that uses RNA, a nucleic acid found in living cells. One type, known as messenger RNA, carries instructions encoded in DNA for cells to follow. Development of mRNA vaccines for diseases such as Covid-19 is faster than traditional vaccine technology because it essentially teaches human cells to produce proteins similar to those found in viruses and provokes an immune response. can do.
GreenLight is one of many companies that are also in a hurry to make mRNA shots of seasonal flu and want to make one to fight the life-threatening blood disorder sickle cell disease. At the same time, we are developing sustainable pesticide alternatives using a process called RNA interference that regulates the production of proteins essential for certain pests.
RNA Tech Firm GreenLight Biosciences Listed on $ 1.5 Billion SPAC Transaction
Source link RNA Tech Firm GreenLight Biosciences Listed on $ 1.5 Billion SPAC Transaction